Skip to main content

InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) New Middle East-North Africa Distribution Deal Spotlighted in Proactive Interview

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from a variety of health conditions, many of which are associated with breathing-related sleep conditions arising from certain dentofacial abnormalities, is spotlighted in a recent Proactive feature interview. During the interview, Vivos Therapeutics CEO Kirk Huntsman chats with Proactive host Steve Darling about recent company news, including an exclusive distribution agreement Vivos just signed with Dubai-based NOUM DMCC (“NOUM DMCC”). NOUM is focused on diagnostic testing and the distribution of treatment products for healthcare providers and hospital networks specializing in obstructive sleep apnea (“OSA”) patients across the Middle East-North Africa (“MENA”) region.

During the interview, Huntsman explained the significance of this partnership and how it addresses the growing demand for effective treatment alternatives to Continuous Positive Airway Pressure (“CPAP”) for individuals suffering from OSA. According to the agreement, Vivos has granted NOUM exclusive distribution rights for its innovative products and services in several key MENA countries, including Saudi Arabia, the United Arab Emirates, Qatar, Kuwait, Bahrain, Oman, Jordan, Lebanon and Palestine. In addition, NOUM will promptly initiate the process of seeking regulatory approvals for Vivos’ medical devices within these countries, with anticipated approval timelines varying from a few weeks to several months. Huntsman also noted that the company’s flagship daytime-nighttime appliance is slated to undergo a clinical trial at Stanford Medicine, with participant enrollment scheduled to begin early 2024. The trial is a milestone for Vivos because it could validate the efficacy of the company’s proprietary appliance in addressing OSA.

To view the full interview, visit

To view the full press release, visit

About Vivos Therapeutics Inc.

Vivos Therapeutics is a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from breathing and sleep issues arising from certain dentofacial abnormalities such as mild-to-moderate obstructive sleep apnea (“OSA”) and snoring in adults. The Vivos Method represents the first clinically effective, nonsurgical, noninvasive, nonpharmaceutical and cost-effective solution for treating mild to moderate OSA. It has proven effective in the treatment of more than 40,000 patients worldwide by more than 1,800 trained dentists. The Vivos Method includes the Vivos Complete Airway Repositioning and/or Expansion (“CARE”) appliance therapy and associated protocols that alter the size, shape and position of the soft tissues that comprise a patient’s upper airway and palate. The Vivos Method opens airway space and may significantly reduce symptoms and conditions associated with mild to moderate OSA, such as lowering Apnea Hypopnea Index scores. Vivos also markets and distributes SleepImage diagnostic technology under its VivoScore program for home sleep testing in adults and children. The Vivos Integrated Practice (“VIP”) program offers dentist training and other value-added services in connection with using the Vivos Method. For more information about this company, visit

NOTE TO INVESTORS: The latest news and updates relating to VVOS are available in the company’s newsroom at

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published:

Los Angeles, CA
310.299.1717 Office

InvestorWire is powered by IBN

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.